*Corresponding author:Pham Cam Phuong, The Gene - Stem Cell Unit, The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam
Received: September 11, 2018; Published: September 17, 2018
To view the Full Article Peer-reviewed Article PDF
Objective: Among more than 40 mutations identified in the BRAF gene, the BRAF T1799A (V600E) point mutation is the most common and accounts for more than 90% of all the mutations found in the BRAF gene. It has been found to occur frequently in thyroid cancer. While some reports suggest the BRAF V600E mutation is associated with poor prognosis and recurrence or iodine uptake resistance, this remains a controversial issue. The aim of study was to: 1) determine the status of BRAF mutation in differentiated thyroid cancer in Bach Mai hospital; 2) evaluate the association of the BRAF mutation with clinicopathological parameters.
Patients and Methods: Retrospective analysis of the BRAF V600E mutation in differentiated thyroid cancer in 198 patients from November 2015 to March 2017 at Bach Mai hospital using BRAF-Strip Assay® (Vienna Lab). The results were correlated with clinicopathological factors.
Results: The BRAF V600E mutation was detected in 150 cases (75.8%). BRAF mutation was found in 69/92 (75%) patients having metastasis. Mutation was found in distant metastasis, lymph node metastasis and in both distant-lymph node metastasis: 63/84 (75%), 9/13 (69.2%) and 3/5 (60%), respectively. Among differentiated thyroid cancer, BRAF mutation was detected in follicular-papillary thyroid cancer (80%), papillary thyroid cancer (76.6%) and in follicular thyroid cancer (40%). There was no significant correlation between the presence of BRAF mutation and clinicopathological factors. Conclusions: The BRAF mutation rate in thyroid cancer patients is high, especially for follicular-derived papillary and papillary thyroid cancer. The lack of a statistically significant association of BRAF and clinical characteristics indicates the need of conducting research with larger sample sizes in the future.